Inactive Instrument

Bioqual, Inc. Stock Other OTC

Equities

BIOQ

US09065J1016

Biotechnology & Medical Research

Sales 2022 66.15M Sales 2023 62.66M Capitalization 67.98M
Net income 2022 5M Net income 2023 - EV / Sales 2022 1.2 x
Net Debt 2022 16.54M Net Debt 2023 11.33M EV / Sales 2023 1.27 x
P/E ratio 2022
11.9 x
P/E ratio 2023
81.7 x
Employees -
Yield 2022
1.43%
Yield 2023
0.66%
Free-Float 55.92%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 69 03-07-31
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 22-05-08
Members of the board TitleAgeSince
Director/Board Member 87 14-12-31
Chief Executive Officer 69 03-07-31
Director/Board Member - -
More insiders
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
More about the company